Abstract:Oligodendrocytes (OLGs), the myelin-forming cells of the central nervous system (CNS), are lifelong partners of neurons. They adjust to the functional demands of neurons over the course of a lifetime to meet the functional needs of a healthy CNS. When this functional interplay breaks down, CNS degeneration follows. OLG processes are essential features for OLGs being able to connect with the neurons. As many as fifty cellular processes from a single OLG reach and wrap an equal number of axonal segments. The cel… Show more
“…In contrast, 4R‐Tau shows higher affinity and more efficiency at promoting microtubule assembly. 3R‐Tau is abundant in the neonatal brain and in immature oligodendrocytes cultured in vitro, whereas 4R‐Tau is profuse in the adult brain and mature oligodendrocyte cultures (Gorath et al, 2001; LoPresti, 2018). Our in vivo results, using immunofluorescence with isoform‐specific antibodies, indicate that 3R‐Tau and 4R‐Tau are present in the brains of healthy adult rats and that they have a similar distribution in interfascicular oligodendrocytes (mature) of the corpus callosum, mainly in the soma around the nucleus, a similar pattern of distribution to that found in mouse brain oligodendrocytes using antitotal tau antibodies (Kubo et al, 2019).…”
Ischemic stroke is a major cause of death and the first leading cause of long-term disability worldwide. The only therapeutic strategy available to date is reperfusion and not all the patients are suitable for this treatment. Blood flow blockage or reduction leads to considerable brain damage, affecting both gray and white matter. The detrimental effects of ischemia have been studied extensively in the former but not in the latter. Previous reports indicate that preservation of white matter integrity reduces deleterious effect of ischemia on the brain. Oligodendrocytes are sensitive to ischemic damage, however, some reports demonstrate that oligodendrogenesis occurs after ischemia. These glial cells have a complex cytoskeletal network, including tau, that plays a key role to proper myelination. 4R-Tau/3R-Tau, which differ in the pres
“…In contrast, 4R‐Tau shows higher affinity and more efficiency at promoting microtubule assembly. 3R‐Tau is abundant in the neonatal brain and in immature oligodendrocytes cultured in vitro, whereas 4R‐Tau is profuse in the adult brain and mature oligodendrocyte cultures (Gorath et al, 2001; LoPresti, 2018). Our in vivo results, using immunofluorescence with isoform‐specific antibodies, indicate that 3R‐Tau and 4R‐Tau are present in the brains of healthy adult rats and that they have a similar distribution in interfascicular oligodendrocytes (mature) of the corpus callosum, mainly in the soma around the nucleus, a similar pattern of distribution to that found in mouse brain oligodendrocytes using antitotal tau antibodies (Kubo et al, 2019).…”
Ischemic stroke is a major cause of death and the first leading cause of long-term disability worldwide. The only therapeutic strategy available to date is reperfusion and not all the patients are suitable for this treatment. Blood flow blockage or reduction leads to considerable brain damage, affecting both gray and white matter. The detrimental effects of ischemia have been studied extensively in the former but not in the latter. Previous reports indicate that preservation of white matter integrity reduces deleterious effect of ischemia on the brain. Oligodendrocytes are sensitive to ischemic damage, however, some reports demonstrate that oligodendrogenesis occurs after ischemia. These glial cells have a complex cytoskeletal network, including tau, that plays a key role to proper myelination. 4R-Tau/3R-Tau, which differ in the pres
“…While Schwann cell-specific tau transgenic mice have not been generated, co-expression of tau in neuronal and glial cells, including Schwann cells, has been shown to result in neurodegeneration and Schwann cell death[15]. Tau is similarly toxic to myelinating cells in the CNS as oligodendrocyte-specific tau expression disrupts the maintenance of myelin integrity[7], consistent with in vitro experiments overexpressing tau in cultured oligodendrocytes[16]. Considering these observed consequences of tau expression in glial cells, as well as the critical contribution of glia in the development of the nervous system[17], we set out to determine whether glial tau expression disrupts the development and/or early maintenance of the PNS.…”
Tauopathies are a class of neurodegenerative diseases characterized by the abnormal phosphorylation and accumulation of the microtubule-associated protein, tau, in both neuronal and glial cells. Though tau pathology in glial cells is a prominent feature of many of these disorders, the pathological contribution of these lesions to tauopathy pathogenesis remains largely unknown. Moreover, while tau pathology is predominantly found in the central nervous system, a role for tau in the cells of the peripheral nervous system has been described, though not well characterized. To investigate the effects of glial tau expression on the development and maintenance of the peripheral nervous system, we utilized a Drosophila melanogaster model of tauopathy that expresses human wild-type tau in glial cells during development. We found that glial tau expression during development results in larval locomotor deficits and organismal lethality at the pupal stage, without affecting larval neuromuscular junction synapse development or post-synaptic amplitude. There was, however, a significant decrease in the decay time of synaptic potentials upon repeated stimulation of the motoneuron. Behavioral abnormalities were accompanied by glial cell death, disrupted maintenance of glial-axonal integrity, and the abnormal accumulation of the presynaptic protein, Bruchpilot, in peripheral nerve axons. Together, these data demonstrate that human tau expression in Drosophila glial cells does not affect neuromuscular junction synapse formation during development, but is deleterious to the maintenance of glial-axonal interactions in the peripheral nervous system.
“…HDAC6 also regulates acetylated Tau in OLGs. Tau participates in many aspects of OLG biology, including myelin formation, myelin integrity, and myelin repair [ 68 , 69 , 70 ]. The relationship between HDACi and inflammation is a complex one.…”
Section: Cognition Regulation and Neurodegenerationmentioning
Central nervous system (CNS) neurodegenerative diseases are characterized by faulty intracellular transport, cognition, and aggregate regulation. Traditionally, neuroprotection exerted by histone deacetylase (HDAC) inhibitors (HDACi) has been attributed to the ability of this drug class to promote histone acetylation. However, HDAC6 in the healthy CNS functions via distinct mechanisms, due largely to its cytoplasmic localization. Indeed, in healthy neurons, cytoplasmic HDAC6 regulates the acetylation of a variety of non-histone proteins that are linked to separate functions, i.e., intracellular transport, neurotransmitter release, and aggregate formation. These three HDAC6 activities could work independently or in synergy. Of particular interest, HDAC6 targets the synaptic protein Bruchpilot and neurotransmitter release. In pathological conditions, HDAC6 becomes abundant in the nucleus, with deleterious consequences for transcription regulation and synapses. Thus, HDAC6 plays a leading role in neuronal health or dysfunction. Here, we review recent findings and novel conclusions on the role of HDAC6 in neurodegeneration. Selective studies with pan-HDACi are also included. We propose that an early alteration of HDAC6 undermines synaptic transmission, while altering transport and aggregation, eventually leading to neurodegeneration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.